As June begins, the global markets are witnessing significant movements, particularly in the technology and energy sectors. The demand for AI chips continues to rise, with Nvidia and Samsung at the forefront of this technological surge. Nvidia’s CEO, Jensen Huang, recently unveiled a new chip that integrates AI capabilities directly into laptops and desktops, promising to revolutionize user interaction with AI.
AI Market Momentum
Samsung’s shares have seen a substantial increase, driven by the commencement of shipments of its new HBM4E chip and anticipation of a meeting with Nvidia’s Huang. This surge in demand is reflected in South Korea’s export data, which shows a remarkable 53.2% year-on-year increase in May, marking the fastest growth since 1984. The country’s KOSPI stock index has more than doubled this year, underscoring the robust performance of the tech sector.
However, the picture is different in China, where factory growth has stalled due to declining export demand. Additionally, reports indicate that the U.S. is halting Nvidia chip shipments to Chinese subsidiaries outside China, adding to the complexities of the global chip market.
Geopolitical and Economic Factors
Meanwhile, geopolitical tensions continue to affect energy markets. The U.S.-Iran peace plan has faced setbacks, with fresh military exchanges over the weekend. This has led to a rise in Brent crude prices, which climbed over 3% to approximately $94 per barrel. The energy sector is bracing for a critical month as June progresses, with potential impacts on global energy supplies.
In the U.S., the release of the ISM manufacturing survey for May is anticipated, alongside other significant macroeconomic data, including the U.S. employment report. Analysts are keeping a close eye on central bank meetings this month, which could result in interest rate hikes, further influencing market dynamics.
Despite the dominance of tech stocks, there is interest in other sectors, with the Russell 2000 small-cap index performing comparably to the SOX chip index. Additionally, Revolution Medicines has seen a 20% surge in shares following promising trial results for its pancreatic cancer drug.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
